The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Fresenius Medical Care AG ADR (NYSE: FMS) closed the day trading at $21.63 up 1.12% from the previous closing price of $21.39. In other words, the price has increased by $1.12 from its previous closing price. On the day, 1.33 million shares were traded. FMS stock price reached its highest trading level at $21.65 during the session, while it also had its lowest trading level at $21.02.
Ratios:
For a better understanding of FMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.31. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.81 whereas as Long-Term Debt/Eq ratio is at 0.72.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FMS now has a Market Capitalization of 12628025344 and an Enterprise Value of 16454493184. As of this moment, Fresenius’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.70, and their Forward P/E ratio for the next fiscal year is 8.83. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.58 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at 0.838 whereas that against EBITDA is 6.709.
Stock Price History:
The Beta on a monthly basis for FMS is 0.89, which has changed by -0.072821856 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, FMS has reached a high of $30.46, while it has fallen to a 52-week low of $21.18. The 50-Day Moving Average of the stock is -7.91%, while the 200-Day Moving Average is calculated to be -15.68%.
Shares Statistics:
Over the past 3-months, FMS traded about 466.71K shares per day on average, while over the past 10 days, FMS traded about 495840 shares per day. A total of 579.70M shares are outstanding, with a floating share count of 579.27M. Insiders hold about 0.07% of the company’s shares, while institutions hold 6.23% stake in the company. Shares short for FMS as of 1767139200 were 1755818 with a Short Ratio of 3.76, compared to 1764288000 on 758068.
Dividends & Splits
FMS’s forward annual dividend rate is 0.81, up from 1.44 a year ago. Against a Trailing Annual Dividend Yield of 0.06732118. The stock’s 5-year Average Dividend Yield is 1.3. The current Payout Ratio is 57.49% for FMS, which recently paid a dividend on 2025-05-23 with an ex-dividend date of 2025-05-23. Stock splits for the company last occurred on 2012-12-04 when the company split stock in a 2:1 ratio.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is $0.49, with high estimates of $0.49 and low estimates of $0.49.
Analysts are recommending an EPS of between $3.92 and $1.83 for the fiscal current year, implying an average EPS of $2.6. EPS for the following year is $2.94, with 6.0 analysts recommending between $4.63 and $2.0.
Revenue Estimates
5 analysts predict $4.76B in revenue. The current quarter. It ranges from a high estimate of $5.15B to a low estimate of $3.92B. As of. The current estimate, Fresenius Medical Care AG ADR’s year-ago sales were $5.08BFor the next quarter, 5 analysts are estimating revenue of $4.97B. There is a high estimate of $5.01B for the next quarter, whereas the lowest estimate is $4.94B.
A total of 17 analysts have provided revenue estimates for FMS’s current fiscal year. The highest revenue estimate was $19.83B, while the lowest revenue estimate was $19.2B, resulting in an average revenue estimate of $19.57B. In the same quarter a year ago, actual revenue was $19.34BBased on 18 analysts’ estimates, the company’s revenue will be $20.16B in the next fiscal year. The high estimate is $20.78B and the low estimate is $19.68B.
